Function Health just closed a massive $298 million Series B round at a $2.5 billion valuation, signaling that investors are betting big on AI-powered healthcare platforms. The company, which offers comprehensive lab testing and medical imaging services, is using the funding to launch its Medical Intelligence Lab - a generative AI model trained by doctors to provide personalized health insights from users' medical data.
Function Health just made healthcare AI personal in a way that could reshape how millions of Americans think about their medical data. The company's $298 million Series B round, led by Redpoint Ventures at a $2.5 billion valuation, comes alongside the launch of Medical Intelligence Lab - an ambitious AI platform that promises to turn your scattered health information into actionable insights.
The funding round reads like a who's who of Silicon Valley and beyond. Andreessen Horowitz joined the round, along with NBA stars Blake Griffin and Allen Crabbe, Battery Ventures, and Roku founder Anthony Wood. The $298 million brings Function's total raised to $350 million, reflecting the massive appetite for healthcare AI solutions that can actually deliver on their promises.
"It's not good enough to be in a world where AI exists and not be applying it to your health," CEO Jonathan Swerdlin told TechCrunch. "You should be able to manage your biology. The objective of Function Health is to apply the best available technology to human health."
Here's what makes Function different from the flood of wellness apps and AI health coaches: the company has processed over 50 million lab tests since 2023 across 75 physical locations in the U.S., with plans to nearly triple that footprint to 200 locations by year-end. That's real medical data from real patients, not just fitness tracker metrics.
The Medical Intelligence Lab represents Function's biggest bet yet. Unlike generic health chatbots, this AI model is trained directly by doctors and can analyze your complete medical history - lab results, doctor's notes, medical imaging, even data from wearable devices. The platform meets HIPAA standards and encrypts all user data, addressing the privacy concerns that have plagued other health AI startups.
"Your data and your identity are never for sale," Swerdlin emphasized in the TechCrunch interview. "Every bit of your information is fully encrypted and protected."
Dr. Mark Hyman, Function's co-founder and chief medical officer, is leading the Medical Intelligence Lab alongside chief medical scientist Dr. Dan Sodickson. The doctor-in-the-loop approach sets Function apart in a crowded field that includes competitors like Superpower, Neko Health, and InsideTracker.
The timing couldn't be better for Function's expansion. Healthcare data generation is exploding - from electronic health records to continuous glucose monitors to sleep tracking devices - but most people can't make sense of it all. Function's device-agnostic platform promises to be the connective tissue that turns data overload into personalized health guidance.
For patients, this means asking questions like "Why did my cholesterol spike last month?" and getting answers that factor in your exercise patterns, dietary changes, stress levels, and genetic predispositions. The AI chatbot can surface connections across years of medical data that even experienced doctors might miss.
The healthcare AI market is heating up fast, with Google pushing its Med-PaLM models and Microsoft integrating health AI into its cloud services. But Function's approach - combining physical testing infrastructure with AI analysis - creates a unique moat that pure software plays can't replicate.
Investors are clearly betting that Function's model can scale beyond the wealthy early adopters who typically embrace boutique healthcare services. At a $2.5 billion valuation, the company needs to prove it can democratize personalized medicine, not just cater to the quantified-self crowd.
The expansion to 200 locations by year-end will be a critical test of Function's ability to maintain quality while scaling rapidly. Each new location needs trained staff, lab equipment, and integration with the AI platform - a complex operational challenge that has tripped up other healthcare startups.
Function Health's massive Series B signals that investors are ready to back healthcare AI platforms that combine real medical infrastructure with cutting-edge technology. The company's doctor-trained AI model and expanding network of testing locations could finally bridge the gap between the data we generate and the insights we need to improve our health. But with a $2.5 billion valuation comes enormous pressure to prove this isn't just another overhyped health tech startup - Function needs to demonstrate it can scale personalized medicine beyond early adopters and actually move the needle on population health outcomes.
